PDGFRA and gastrointestinal stromal tumor: Updated results from the phase I NAVIGATOR study reported 84% ORR in patients with the rare D842V and other exon 18 mutations and avapritinib is now considered first-line therapy in the uncommon patients with metastatic GIST with a PDGFRA D842V mutation [23].